SIX CO-LOCATED PROGRAMMES ACROSS ASIA’S BIOPHARMA VALUE CHAIN

23 - 24 March 2027 Sands Expo & Convention Centre, Singapore
The Six Programmes
BMA 2027 White Visit Brochure
ADC 2027 White Visit Brochure
CGTWA 2027 White Visit Brochure
CTFA 2027 White Visit Brochure
OPWA 2027 White Visit Brochure
BSCA 2027 White Visit Brochure
Awards

About the Event

Biopharma APAC Confex 2027 brings six co-located conferences under one roof at the Sands Expo & Convention Centre, Singapore, on 23–24 March 2027: Biologics Manufacturing Asia, ADC Asia Congress, Cell & Gene Therapy World Asia, Clinical Trials Festival Asia, Oligos & Peptides World Asia and Biosupply Chain Asia. One registration, one exhibition floor, and one decision-making community across the modalities reshaping the region’s biopharma pipeline.

Each programme runs its own two-day agenda, so delegates can go deep in their own field and still move freely between the others — the conversations between the programmes are the point of co-locating them. Together the six agendas span process development and biomanufacturing, antibody–drug conjugates, cell and gene therapies, clinical trial design and execution, oligonucleotide and peptide therapeutics, and the supply chain that carries all of them to patients.

What we'll cover

Key Themes

Biologics Manufacturing
Upstream and downstream process development, CMC, analytics and characterisation, formulation, facility engineering and digital manufacturing — from robust cell lines to real-time release.
Antibody–Drug Conjugates
Discovery and next-generation targeting, pre-clinical translation, formulation and stability, and the safety–efficacy balance that decides whether an ADC reaches patients.
Cell & Gene Therapy
CAR-T, gene editing and emerging modalities; vector engineering, delivery and analytics; scale-up, tech transfer and CMC readiness; and the regulatory and market-access routes to commercialisation.
Clinical Trials
APAC trial harmonisation and emerging markets, patient-centric and decentralised designs, digital endpoints and wearables, AI in trial execution, and the logistics behind a multi-country study.
Oligos & Peptides
The RNA and oligonucleotide landscape in APAC, peptide therapeutics, delivery technologies and precision tissue targeting, and manufacturing, CMC and commercial scale-up.
Biopharma Supply Chain
Resilient and future-ready cold chain, next-generation logistics, smart packaging and traceability, sustainability in cold and ambient chains, and GxP compliance across Asian markets.
BY THE NUMBERS

Our Impact in Asia's Biopharma

2000+
Attendees
700+
Companies
250+
Speakers

Testimonials

Hear from past attendees and industry leaders

“The conference provides a forum for latest sharing and networking among biopharma peers from different organisations. The panel discussions are particularly informative as they cover realistic, contemporaneous and first-hand sharing on opportunities and challenges facing the industry and organisations. One key highlight of the conference is the ABEA Night. This prestigious recognition highlights the outstanding contributions of individual leader advancing biopharma excellence in the Asia-Pacific region.”
Vice President & Site Quality Head, Global Quality
Takeda
Singapore flag Singapore
“It was a very valuable conference experience. I was pleased to have the opportunity to present and discuss our technology with peers in the field, which led to several new and meaningful engagements. The meeting also offered a strong scientific programme, and it was inspiring to hear high-quality work from other groups. Beyond the content itself, the conference was especially useful for building new connections and opening the door to potential future collaborations.”
CTO
Singzyme
Singapore flag Singapore
“Thank you so much for organizing such a well-run event. It was truly a pleasure to contribute, and I enjoyed the atmosphere and engagement from the audience during the event.”
Corporate Performance Specialist
Biofarma
Indonesia flag Indonesia
“Overall, we believe the event was very well organized and successful. From an exhibitor’s perspective, the arrangement of 1-to-1 meetings was particularly useful and added significant value.”
Business Development Director
Pfanstiehl
Singapore flag Singapore
"Insights from industry leaders are valuable and cannot be found easily online"
Technical Steward
BioNTech
Singapore flag Singapore
“Thanks for organizing BioSupply Chain Asia, it was a good event and I have learnt a lot.”
Head of Singapore Explore Platform
Sanofi
Singapore flag Singapore
“The team was very friendly and helpful. They were committed to scheduling 1-to-1 meetings and ensuring it went smoothly.”
BDM
SGS
Singapore flag Singapore
“Good team, clever techniques to bring people in contact. Appreciate their effort and help.”
Product & Sales Manager
DrM Group
Switzerland flag Switzerland

Partners 2027

Confirmed partners across all six Biopharma APAC Confex 2027 programmes

Platinum Sponsor
cytiva-logo-vector
Gold Sponsors
Becton_Dickinson_logo.svg
WuXi Biologics
Silver Sponsors
Pfanstiehl-hd
Sartorius Logo
Thermo Fisher Scientific Red BG
BSP logo 1
Bronze Sponsors
Andgel
Wuxi XDC_logo_4C
rest-nona-biosciences
Exhibitors
DYE logo blue 1
Duoning-Logo-EN-small-1
DrM_Logo
PharmNXT Logo_COLOUR_transparent 2K
Single Use Support
Tosoh Bioscience
Truking logo 1
Hycure
Merck
avantor-inc-logo-vector
Meissner Corporation
Aber
Ami Polymer
ORKA Pharma-navyblue transparent
Infors HT
3CON-Logo_Life_Subtitle_Aqua-Grey
IMG_5072
E+H_Claim_rgb_600px_v2
Tofflon
CPC Biotech
Catalent-Pharma Services-TM-Logo-Color-RGB 2
Honya Biotech 1
Qickstat
Associate Sponsors
Uniqculture
Networking Partner
Almac Group
Media & Publicity
Life Sciences Review
BioPharma Asia Logo
Cell & Gene
Nucleic Acid Insights

Meet the Speakers

Across all six Biopharma APAC Confex 2027 programmes

Naveen Jain
Naveen Jain
VP, Pre-Clinical
Panacea Biotec
India flag India
Maneesh Ghildyal
Maneesh Ghildyal
VP & Global Head, Projects & Engineering
Biocon Biologics
India flag India
Matthew Choo, Ph.D.
Matthew Choo, Ph.D.
Associate Director, Data Science
MSD
Singapore flag Singapore
Dr. Shiva Patil
Dr. Shiva Patil
Medical Head, Asia Pharma
Sanofi
Singapore flag Singapore
Andy Xian Zheng, PhD
Andy Xian Zheng, PhD
CEO
Byterna Therapeutics
Singapore flag Singapore
Santi Purwantini
Santi Purwantini
Planning Lead
Organon
Indonesia flag Indonesia
Simon Chuang
Simon Chuang
CEO
HoneyBear Science
Taiwan flag Taiwan
Alap Gandhi
Alap Gandhi
Country Medical Director
GSK
Malaysia flag Malaysia
Teck Chung Chang
Teck Chung Chang
VP, Site Quality Head
Takeda
Singapore flag Singapore
Prasad Deshpande
Prasad Deshpande
President & CTO (Technical Operations)
Shalina Healthcare
India flag India
Bin Xia Yang
Bin Xia Yang
Director
Hengrui R&D Centre
Singapore flag Singapore
Bin Zou
Bin Zou
CEO & Founder
Axcynsis Therapeutics
Singapore flag Singapore
Prof. Waranyoo Phoolcharoen
Prof. Waranyoo Phoolcharoen
CTO & Co-Founder
Baiya Phytopharm Co., Ltd
Thailand flag Thailand
Indira Singampalli
Indira Singampalli
VP, Head Strategic Procurement
Dr. Reddy's Laboratories
Singapore flag Singapore
Prof. Rakesh Veedu
Prof. Rakesh Veedu
Professor/Co-Founder & MD/CEO
Murdoch University/ ProGenis Pharmaceuticals
Australia flag Australia
Won Gyun Ahn
Won Gyun Ahn
Associate Director
Qurient
South Korea flag South Korea
Dr. Miles Shi
Dr. Miles Shi
Chief Technology Officer
Etana Biotechnologies
Indonesia flag Indonesia
Emma Dernelley
Emma Dernelley
Senior Director, Distribution & Regional Quality APAC
BeOne Medicines
Australia flag Australia
Wonil Kim
Wonil Kim
CSO
Aston Sci
South Korea flag South Korea
Doo Young Jung
Doo Young Jung
Chief Executive Officer
PinotBio
South Korea flag South Korea
Sandeep Majumdar
Sandeep Majumdar
Executive Vice President, Zydus Biologics
Zydus Group
India flag India
Dr. Pratik Dave
Dr. Pratik Dave
Senior Scientist
Roche
Switzerland flag Switzerland
Vighnesh Balla
Vighnesh Balla
Head of Site Engineering and Maintenance
Sanofi
Singapore flag Singapore
Dr. Bharti Prafulla Deshmukh
Dr. Bharti Prafulla Deshmukh
HOD of RND Peptide Genric
Hovid Bhd
Malaysia flag Malaysia
Chris Chan
Chris Chan
Head of Supply Chain, APAC
Ipsen
Singapore flag Singapore
Stephen Lin
Stephen Lin
Vice General Manager
ExoOne Bio
Taiwan flag Taiwan

Agenda at a Glance

CONFERENCE DAY 1 | Tuesday, 23 March 2027
Biologics Manufacturing Asia 2027 ADC Asia Congress 2027 Cell & Gene Therapy World Asia 2027 Clinical Trials Festival Asia 2027 Oligos & Peptides World Asia 2027 Biosupply Chain Asia 2027
Track 1Track 2
Leadership Panel Discussion
Building Asia’s Global Leadership in Biologics Manufacturing & Innovation
Leadership Panel Discussion
Building Asia’s Global Leadership in ADCs
Next-Generation Cell & Gene Therapies
CAR-T, Gene Editing & Emerging Modalities
APAC Trial Harmonization & Emerging Markets
Multi-country Trial Design and Next-wave Market Spotlight
Asia’s Frontier in Oligonucleotide Therapeutic
Building Resilient Cold Chain & Future-Ready Biopharma Supply Chains in Asia
Morning Break, Exhibition Viewing & 1-1 Networking
Upstream Processing
Robust Cell Lines & Optimized Expression Systems
Downstream Processing
Advancing Final Product Quality: Polishing, Viral Clearance & Formulation
Discovery
Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
From Discovery to Clinical Translation
Accelerating CGT Development
Navigating the Future of Patient-Centric Trials
Recruitment, Retention, and Patient Diversity
Peptide Therapeutics 2.0
Beyond GLP-1
Next-Gen Cold Chain Logistics
 Real-Time Visibility with Smart Devices 
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Upstream Processing
Process Intensification Strategies: Perfusion, Fed-Batch & High-Density Strategies
Analytics & Characterization
Next-Generation Methods for Product Quality & Process Excellence
Advancing Pre-Clinical Research
Bringing the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
Gene & Cell Therapy Platforms
Vector Engineering, Delivery & Analytics 
Advancing Pre-Clinical Research
Bridging the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
Breaking the Delivery Barrier
From Oral Peptides to Precision Oligos
Driving Sustainability in Cold and Ambient Chain Logistics
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Downstream Processing
Refining Primary Recovery: Product Capture, Impurity Removal & Novel Methods
MSAT & Tech Transfer Excellence
Scale-Up, Validation & Lifecycle Management
Formulation & Stability
Ensuring ADC Stability & Optimized Formulation for Maximum Efficacy
Smart Manufacturing & Process Development for CGTs
Decentralized Trials, Digital Endpoints, and Wearables
Convergence
Peptide - Oligonucleotide Conjugates & Hybrid Modalities
Smart Packaging & Traceability for Temperature-Sensitive Biologics
End of Conference Day 1
CONFERENCE DAY 2 | Wednesday, 24 March 2027
Biologics Manufacturing Asia 2027 ADC Asia Congress 2027 Cell & Gene Therapy World Asia 2027 Clinical Trials Festival Asia 2027 Oligos & Peptides World Asia 2027 Biosupply Chain Asia 2027
Track 1Track 2
CMC, Analytics & Quality
Achieving CMC Excellence, Integrated Analytics, Quality Control & Regulatory Readiness
Advancing Payloads and Linker Technologies for Next-Generation ADCs
Advanced Cell Therapies
Beyond Traditional CAR-T
AI & Digital Transformation in Trial Execution
AI in Feasibility, eSource, Protocol Design
From Asia to Global Clinical Development & Regulatory Approval
Smart Supply Chain 4.0
 Predictive Logistics, AI, Blockchain & Automation Use Cases
Morning Break, Exhibition Viewing & 1-1 Networking
Formulation, Development & Manufacturing
Stability, Drug Product Design & Commercialization
Smart, Agile and Digital Manufacturing
Flexible Facilities, Digital First Operations and Single Use System
Safety and Efficacy
Balancing Safety and Efficacy in ADCs: Overcoming Challenges for Effective Treatment
Manufacturing Excellence
Scale-Up, Tech Transfer & CMC Readiness 
Transforming Clinical Trial Logistics in APAC
Oligonucleotide Manufacturing
From Synthesis to Commercial Scale
Transforming Clinical Trial Logistics in APAC
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Process Analytics & Real-Time Manufacturing
PAT, Advanced Monitoring & Real-Time Release
Facility Engineering & Infrastructure Excellence
Designing, Operating & Future-Proofing Next-Generation Biomanufacturing Facilities
ADC Biopharma Showcase
Pioneering Innovation and Excellence in Antibody-Drug Conjugates
Supply Chain & Operational Excellence for CGTs
APAC Showcase
From Early-Phase to Late-Stage: Showcasing End-to-End Clinical Research Capabilities
Peptide Manufacturing
Scale, Cost & GMP Readiness
Meeting Regulatory Expectations & GxP Compliance in Asia
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Closing Roundtable Discussion
Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
Closing Roundtable Discussion:
Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
Regulatory Pathways, Market Access & Commercialization
Closing Panel Discussion
Rethinking Clinical Development as a Continuous Journey
Closing Roundtable Discussion
Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
Leadership Panel
 Future-Proofing Biopharma Supply Chains in Asia 2027–2030
End of Conference Day 2
FULL AGENDA

Choose a programme

BIOLOGICS MANUFACTURING ASIA 2027

Day 1

Tuesday, 23 March 2027

Track 1
Track 2
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
TRACK
Building Asia’s Global Leadership in Biologics Manufacturing & Innovation
9:00
Leadership Panel Discussion: Asia’s Biologics Ambition: From Regional Manufacturing Hub to Global Innovation Powerhouse
  • Evaluating Asia’s competitive advantage in biologics development, manufacturing, and commercialization.
  • Identifying critical investments required in talent, infrastructure, and technology to compete globally.
  • Strengthening regional collaboration between governments, industry, academia, and investors.
  • Building resilient and future-ready biologics ecosystems capable of supporting next-generation therapeutics.
PANELISTS
Teck Chung Chang
Teck Chung Chang
VP, Site Quality Head, Takeda
9:50
Accelerating Biologics Manufacturing: Powering Asia’s Global Leadership
  • Leveraging next-generation technologies to accelerate biologics development and scale-up.
  • Advancing upstream, downstream and analytical capabilities for greater efficiency and quality.
  • Using automation, AI and digital tools to strengthen manufacturing performance.
  • Building Asia’s competitiveness as a global biologics manufacturing hub.
Reserved for Solution Providers
10:05
Advancing Biologics Development: Enhancing Speed, Quality and Commercial Readiness
  • Implementing platform-based approaches to accelerate biologics development timelines.
  • Improving cell line development, process development, and analytical characterization strategies.
  • Managing technology transfer and global manufacturing network expansion.
  • Balancing innovation, cost-efficiency, and regulatory compliance throughout product development.
Sandeep Majumdar
Sandeep Majumdar
Executive Vice President, Zydus Biologics, Zydus Group
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Upstream Processing — Robust Cell Lines & Optimized Expression Systems
TRACK
Downstream Processing — Advancing Final Product Quality: Polishing, Viral Clearance & Formulation
11:15
Engineering Next-Generation Cell Lines for High Productivity, Stability & Product Quality
  • Balancing productivity, genetic stability, and critical quality attributes (CQAs) during cell line development.
  • Leveraging CRISPR, targeted integration, and host cell engineering to create robust production cell lines.
  • Strategies to address difficult-to-express proteins, bispecific antibodies, and novel biologic modalities.
  • Accelerating clone selection and characterization while maintaining regulatory compliance and manufacturability
11:15
Doing More with Less: Reducing Buffers, Water, Resin and Waste in Downstream Processing
  • Addressing the growing buffer and water footprint of large-scale biologics purification.
  • Exploring buffer concentrates, inline conditioning and alternative chromatography approaches.
  • Extending resin lifetime while maintaining cleaning effectiveness and product quality.
  • Connecting DSP sustainability improvements with manufacturing cost and facility capacity objectives.
11:40
AI, Automation & Digital Cell Line Development: Accelerating the Path to High-Producing Clones
  • How AI and machine learning are transforming clone selection, cell line screening, and process optimization.
  • Digital platforms, automated single-cell cloning, and high-throughput technologies enabling faster development cycles.
  • Using predictive analytics to improve manufacturability, productivity, and product quality outcomes.
  • Case studies demonstrating reduced timelines and increased success rates through digitalized cell line development
Reserved for Solution Providers
11:40
Polishing Under Pressure: Removing HCPs, Aggregates and Process-Related Impurities at Higher Titres
  • Designing robust polishing strategies for increasingly concentrated and complex feed streams.
  • Tackling difficult-to-remove host cell proteins, DNA, aggregates and leachables.
  • Optimising resin selection, loading capacity and operating conditions to reduce purification cycles.
  • Applying advanced analytics to understand impurity behaviour and strengthen clearance validation
Reserved for Solution Providers
11:55
Enhancing Upstream Productivity Through Advanced Media and Feed Optimization
  • Designing chemically defined media for improved cell performance.
  • Optimizing feeding strategies to maximize yield and viability.
  • Leveraging metabolomics for media development.
  • Real-world examples of process intensification through media optimization.
11:55
Formulation at Higher Concentrations: Solving Stability, Viscosity and Aggregation Challenges
  • Developing high-concentration formulations for subcutaneous and patient-friendly delivery.
  • Managing viscosity, aggregation, particle formation and protein–protein interactions.
  • Optimising excipient selection and formulation conditions to preserve long-term stability.
  • Integrating formulation development earlier with upstream and downstream process development.
12:20
Lunch – Exhibition Viewing & 1-1 Networking
TRACK
Upstream Processing: Process Intensification Strategies: Perfusion, Fed-Batch & High- Density Strategies
TRACK
Analytics & Characterization: Next-Generation Methods for Product Quality & Process Excellence
2:05
Beyond Titre: Redefining Upstream Productivity Through High-Density Process Intensification
  • Benchmark perfusion, intensified fed-batch and conventional fed-batch across titre, volumetric productivity and facility throughput.
  • Optimise cell-specific productivity, viable cell density and culture longevity without compromising CQAs.
  • Manage oxygen transfer, CO₂ accumulation, osmolality and nutrient limitations at ultra-high cell densities.
  • Determine when higher upstream productivity translates into lower COGS and smaller manufacturing footprints.
2:05
Multi-Attribute Methods 2.0: Moving MAM from Characterization into Routine QC and Product Release
  • Expanding LC-MS-based MAM from development laboratories toward QC environments for simultaneous monitoring of multiple product quality attributes.
  • Tackling method robustness, validation, data processing and comparability challenges associated with routine MAM implementation.
  • Evaluating how MAM can complement or replace conventional analytical assays without increasing regulatory risk.
  • Building regulatory confidence and harmonised implementation strategies across differing APAC market requirements.
2:30
Intensified Fed-Batch 2.0: Pushing Cell Density Without Pushing Process Risk
  • Design high-density seed trains and N-1 perfusion strategies to shorten production bioreactor occupancy.
  • Optimise inoculation density, feeding profiles and metabolic control for accelerated production cycles.
  • Prevent lactate, ammonia and other inhibitory metabolite accumulation at elevated biomass levels.
  • Evaluate the productivity-versus-complexity trade-off compared with full perfusion.
Reserved for Solution Provider
2:30
AI-Enabled Analytical Development: From Data-Rich Experiments to Faster Quality Decisions
  • Applying AI/ML to analytical method development, optimization, and interpretation of complex datasets.
  • Connecting PAT, process, and laboratory data to identify emerging quality trends.
  • Using predictive analytics to anticipate deviations, OOS/OOT results, and process drift.
  • Addressing model validation, data integrity, explainability, and regulatory acceptance across APAC
Reserved for Solution Provider
2:45
Intensification Without Compromise: Controlling CQAs in High-Density and Continuous Cultures
  • Understand how prolonged culture duration and altered cellular metabolism influence glycosylation, charge variants and aggregation.
  • Define CPP–CQA relationships specifically for perfusion and high-density processes.
  • Establish comparability strategies when transitioning commercial molecules from conventional fed-batch to intensified platforms.
  • Build control strategies that satisfy evolving expectations for continuous and intensified biomanufacturing in APAC.
2:45
Next-Generation Impurity Analytics: Detecting the Unknowns Before They Become a Quality Risk
  • Advancing detection and quantification of host-cell proteins, residual DNA, aggregates, fragments, process-related impurities and product variants.
  • Applying high-resolution MS, NGS and orthogonal analytical technologies to detect low-abundance and previously unidentified impurities.
  • Connecting impurity profiles with upstream and downstream process parameters to improve root-cause analysis and clearance strategies.
  • Developing risk-based impurity control strategies that remain robust through process changes, scale-up and technology transfer.
3:10
Breaking the Density Barrier: Engineering Robust High-Cell-Density Cultures at Commercial Scale
  • Optimising cell-line performance, media composition, feeding strategies, and process parameters at ultra-high cell densities.
  • Addressing oxygen transfer, CO₂ accumulation, osmolality, metabolite build-up, and mixing limitations as density increases.
  • Understanding how intensified culture conditions influence CQAs, glycosylation, aggregation, and product consistency.
  • Translating high-density performance from development-scale bioreactors into reliable GMP manufacturing.
Reserved for Solution Provider
3:10
Beyond Manual Testing: Accelerating Quality Decisions Through Automated Analytics
  • Advancing automated sample preparation, testing and data analysis to improve throughput, reproducibility and right-first-time results.
  • Integrating robotics, miniaturised assays and high-throughput analytical platforms to accelerate testing across development and commercial manufacturing.
  • Connecting laboratory automation with LIMS, ELN and manufacturing systems to enable seamless data flow and faster quality decisions.
  • Overcoming APAC implementation barriers around validation, legacy-system integration, workforce readiness and investment justification.
Reserved for Solution Provider
3:25
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Downstream Processing — Refining Primary Recovery: Product Capture, Impurity Removal & Novel Methods
TRACK
MSAT & Tech Transfer Excellence: Scale-Up, Validation & Lifecycle Management
4:10
Panel Discussion: Driving Down Cost of Goods: Maximising Downstream Productivity, Efficiency & Facility Utilisation
  • Optimising resin utilisation, buffer consumption and water demand while maintaining yield, purity and critical quality attributes.
  • Leveraging buffer concentrates, inline conditioning and inline dilution to reduce preparation burden, storage requirements and facility complexity.
  • Applying downstream process intensification to increase throughput and capacity within brownfield and space-constrained APAC manufacturing facilities.
  • Translating DSP improvements into measurable gains in cost per batch, cost per gram, facility utilisation and manufacturing capacity.
4:10
Panel Discussion: Tech Transfer Under Pressure: Achieving Right-First-Time Transfer Across APAC Manufacturing Networks
  • Identifying hidden gaps between sending-unit process knowledge and receiving-site capabilities
  • Assessing equipment, facility, raw-material and analytical differences before transfer execution
  • Establishing clear MSAT, process development, quality, engineering and manufacturing ownership
  • Developing readiness metrics and stage-gate models to reduce deviations and repeat engineering runs
4:40
Smarter Impurity Clearance: Tackling HCP, DNA, Aggregates & Process-Related Contaminants
  • Understanding how intensified upstream processes change host-cell protein and impurity profiles.
  • Improving removal of HCP, residual DNA, aggregates, leachables and other process-related impurities.
  • Applying orthogonal purification strategies to address difficult-to-remove contaminants.
  • Using enhanced analytics to understand impurity trajectories and optimise downstream unit operations.
Reserved for Solution Provider
4:40
From Development to Commercial Scale: De-Risking Biologics Scale-Up Without Losing Process Performance
  • Translating small-scale process understanding into robust commercial-scale operating ranges
  • Managing scale-dependent CPPs, mass transfer, mixing, shear and bioreactor geometry
  • Using engineering runs, scale-down models and risk assessments to predict scale-up failure
  • Building MSAT strategies that shorten the path from clinical manufacturing to PPQ
Reserved for Solution Provider
4:55
Capture Chromatography Under Pressure: Extending Resin Lifetime Without Compromising Product Quality
  • Optimising Protein A loading, cycling and resin utilisation as titres continue to increase.
  • Controlling resin fouling, ligand leaching and performance deterioration over extended campaigns.
  • Evaluating high-capacity resins, membranes and alternative affinity technologies to reduce capture bottlenecks.
  • Building resin lifecycle and cleaning strategies suited to APAC's growing multi-product manufacturing environment.
4:55
Scaling Plant-Based Biologics: Translating Alternative Expression Platforms from Development to Commercial Manufacturing
  • Translating plant-based expression platforms from R&D into scalable and reproducible biologics manufacturing
  • Managing scale-up challenges while maintaining yield, consistency, product quality, and process performance
  • Identifying and mitigating manufacturing risks associated with alternative expression platforms during technology transfer and scale-up
  • Lessons learned in building manufacturing readiness and scalability for next-generation biologics platforms
Prof. Waranyoo Phoolcharoen
Prof. Waranyoo Phoolcharoen
CTO & Co-Founder, Baiya Phytopharm Co., Ltd
5:20
Continuous & Intensified Downstream Processing: Moving from Unit Operations to Integrated Purification
  • Integrating continuous chromatography, filtration and buffer management into connected downstream workflows.
  • Overcoming process-control and equipment-integration challenges associated with continuous manufacturing.
  • Using PAT and real-time monitoring to maintain critical quality attributes during intensified processing.
  • Determining where continuous downstream processing delivers meaningful productivity and COGS advantages in APAC.
5:20
Managing Change Without Revalidating Everything: Smarter Lifecycle & Post-Approval Change Management
  • Applying science- and risk-based approaches to determine the validation impact of process changes
  • Leveraging established conditions and Post-Approval Change Management Protocols
  • Managing equipment, raw-material, scale and site changes without compromising the validated state
  • Navigating different APAC expectations for variations and post-approval CMC changes
5:45
Chairman’s Closing Remarks
5:50
End of day 1
6:00
Cocktails & Networking
6:30
Asia Pacific Biopharma Excellence Awards 2027 | Gala Dinner
BIOLOGICS MANUFACTURING ASIA 2027

Day 2

Wednesday, 24 March 2027

Track 1
Track 2
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
TRACK
CMC, Analytics & Quality Achieving CMC Excellence, Integrated Analytics, Quality Control & Regulatory Readiness (Combined Track 1 and Track 2)
9:00
Regulatory-Ready CMC: Designing Global Development Programs for FDA, EMA & APAC Expectations
  • Building CMC strategies that anticipate evolving requirements across FDA, EMA and key APAC regulators.
  • Aligning analytical validation, process validation, comparability and stability strategies for global submissions.
  • Managing post-approval changes, manufacturing changes and lifecycle comparability without disrupting supply.
  • Strengthening regulatory engagement and documentation to reduce CMC questions, review cycles and approval delays.
9:50
Platform Analytics: Leveraging Analytical Methods Across Products and Development Pipelines
  • Establishing platform analytical procedures that can be applied across related molecules, modalities, and product families while maintaining product-specific scientific rigor.
  • Streamlining method development, qualification, and validation by leveraging prior analytical knowledge and proven platform capabilities.
  • Designing robust bridging and method-transfer strategies across products, manufacturing sites, QC laboratories, and global testing networks.
  • Defining the scientific evidence, comparability data, and regulatory justification required to support the use of platform methods across multiple products.
Reserved for Solution Providers
10:05
Comparability Under Pressure: Managing CMC Change Across Scale-Up, Tech Transfer & Manufacturing Networks
  • Designing comparability strategies for process changes, scale-up, site transfers, and manufacturing expansion.
  • Determining when analytical comparability is sufficient and when additional non-clinical or clinical evidence may be required.
  • Using orthogonal and advanced characterization methods to demonstrate product consistency.
  • Building change management strategies that enable manufacturing flexibility without creating regulatory delays.
10:30
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Formulation, Development & Manufacturing: — Stability, Drug Product Design & Commercialization
TRACK
Smart, Agile and Digital Manufacturing — Flexible Facilities, Digital First Operations and Single Use System
11:15
From Molecule to Medicine: Designing Drug Products for Stability, Delivery & Manufacturability
  • Translating molecule characteristics into the right formulation and dosage-form strategy.
  • Balancing potency, concentration, viscosity, stability, and patient usability.
  • Applying QbD to identify critical quality attributes and formulation design space.
  • Avoiding late-stage redesign by integrating manufacturing requirements from the outset.
11:15
From Fixed to Flexible: Designing Multi-Product Facilities for Asia’s Changing Biologics Pipeline
  • Designing facilities that can rapidly switch between products, modalities, and batch sizes.
  • Balancing ballroom, modular, and traditional facility configurations for different manufacturing needs.
  • Minimising changeover time, cross-contamination risk, and production downtime in multi-product environments.
  • Building flexibility into utilities, equipment, automation, and process flows without overengineering capacity.
11:40
Freeze, Dry or Reformulate? Advancing Lyophilization & Alternative Stability Strategies
  • Determining when lyophilization offers advantages over liquid formulations.
  • Optimizing freezing, primary drying, secondary drying, and cycle development.
  • Applying modeling and PAT to improve lyophilization robustness and cycle efficiency.
  • Scaling lyophilization processes while maintaining critical quality attributes and product stability.
Reserved for Solution Providers
11:40
Single-Use at Scale: Solving Cost, Supply and Sustainability Constraints
  • Where single-use technologies deliver the strongest operational and economic advantages versus stainless steel.
  • Addressing extractables/leachables, integrity, standardisation, and supplier qualification challenges.
  • Reducing dependence on imported consumables through stronger regional supply networks and dual sourcing.
  • Tackling plastic waste and developing credible sustainability strategies for disposable manufacturing systems.
11:55
Formulation Under Pressure: Solving Stability Challenges Before They Derail Development
  • Identifying degradation pathways and critical stability risks earlier in development.
  • Tackling aggregation, oxidation, deamidation, hydrolysis, and other product-specific liabilities.
  • Using predictive stability models and accelerated studies to guide formulation decisions.
  • Building stability-indicating strategies that support longer shelf life and commercialization.
11:55
Building Agile Biologics Operations: Balancing Manufacturing Capacity, Cost and Supply Resilience
  • Designing flexible manufacturing operations to support multiple biologics products and changing pipeline demands
  • Balancing capacity utilization, manufacturing cost, CAPEX and operational efficiency
  • Integrating manufacturing, engineering, quality, digitalization and supply chain for more agile operations
  • Building supply resilience and facility readiness while scaling biologics manufacturing across Asia
Dr. Miles Shi
Dr. Miles Shi
Chief Technology Officer, Etana Biotechnologies
12:20
Lunch – Exhibition Viewing & 1-1 Networking
TRACK
Process Analytics & Real-Time Manufacturing: — PAT, Advanced Monitoring & Real-Time Release
TRACK
Facility Engineering & Infrastructure Excellence: Designing, Operating & Future-Proofing Next-Generation Biomanufacturing Facilities
2:05
From PAT to RTRT: Building the Roadmap to Real-Time Release in Biologics
  • Translating PAT data into defensible real-time release strategies for biologics.
  • Connecting CPPs, CQAs and in-process measurements to release decisions.
  • Validating PAT models and demonstrating continued model performance.
  • Regulatory and operational barriers to moving from conventional QC release to RTRT.
2:05
From Design to GMP Operations: De-Risking Commissioning, Qualification & Facility Start-Up
  • Integrating C&Q requirements from concept and detailed design stages
  • Risk-based commissioning and qualification of facilities and utilities
  • Improving handover between engineering, validation, quality and operations
  • Avoiding common start-up failures that delay GMP readiness and production
2:30
Soft Sensors & Virtual Measurements: Predicting What You Cannot Measure In-Line
  • Developing soft sensors for CQAs that cannot be directly measured continuously.
  • Combining process data, mechanistic models and multivariate analytics.
  • Model calibration, validation and lifecycle management across batches and sites.
  • Using predictive signals for earlier deviation detection and proactive intervention.
Reserved for Solution Providers
2:30
Engineering the Cleanroom of the Future: Smarter HVAC, Zoning & Energy Optimization
  • Optimizing air-change rates without compromising GMP requirements
  • Risk-based cleanroom classification and HVAC zoning
  • Applying CFD and dynamic environmental control to facility design
  • Reducing HVAC energy consumption and lifecycle operating costs
Reserved for Solution Provider
2:45
PAT Across the Bioprocess: Connecting Upstream, Downstream & Product Quality
  • Deploying PAT from cell culture and harvest through chromatography and formulation
  • Monitoring CQAs and CPPs across interconnected unit operations
  • Connecting upstream variability with downstream purification performance
  • Building an integrated analytical control strategy instead of isolated PAT applications
2:45
Contamination Control by Design: Engineering Facilities for Annex 1 & PIC/S Readiness
  • Embedding contamination control strategy into facility layout and engineering design
  • Engineering pressure cascades, segregation and personnel/material flows
  • Integrating barrier technologies, environmental monitoring and closed processing
  • Designing facilities that maintain inspection readiness throughout their operational lifecycle
3:10
Digital Twins for Biologics: From Process Simulation to Real-Time Control
  • Developing hybrid digital twins using first-principles models and manufacturing data
  • Connecting PAT measurements to continuously update process-state estimates
  • Predicting deviations, yield and product-quality outcomes before they occur
  • Using digital twins for scale-up, process optimization, operator decision support and control
3:10
Capacity Without Overbuilding: Engineering the Right Facility for Asia's Next Biologics Pipeline
  • Using dynamic capacity modelling to determine facility size and configuration
  • Balancing current demand against uncertain future pipeline requirements
  • Deciding when to expand, retrofit, modularize or build greenfield capacity
  • Avoiding over-engineering while retaining sufficient flexibility for future products and technologies
3:35
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
TRACK
Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
4:20
Biologics Manufacturing Asia
  • Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
  • Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
  • CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?
ADC Asia Congress
  • Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
  • From Bench to Bedside: What’s Missing in Translating Preclinical ADC Wins to Clinical Success?
  • Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities
BioSupply Chain Asia
  • Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
  • Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
  • Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?
Clinical Trial Asia
  • Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
  • Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?
Oligos & Peptides Asia
  • Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
  • Beyond Purity: Managing Peptide Aggregation, Degradation & Stability
5:20
Chairman’s Closing Remarks
5:30
End of day 2
ADC ASIA CONGRESS 2027

Day 1

Tuesday, 23 March 2027

8:50
Chairman Opening Remarks
9:00
Panel Discussion: Platform to Pipeline: What It Takes to Win in APAC's ADC Race
  • Comparing conjugation and payload strategies driving differentiation among leading APAC ADC platforms
  • Navigating licensing, out-licensing, and Western partnership deals from a China/APAC vantage point
  • Scaling from platform validation to clinical and manufacturing readiness in a capacity-constrained market
9:25
Accelerating Development Timelines: Innovative Technologies for ADCs
  • Showcasing next-generation technologies enabling faster process development and optimization.
  • Exploring advanced analytical tools for improving product characterization and quality control.
  • Examining innovations in conjugation, formulation, and delivery technologies for ADCs and novel therapeutics.
  • Discussing how technology providers and CDMOs can support rapid clinical and commercial manufacturing.
Reserved for Solution Provider
9:50
Advancing ADC Development: Enhancing Speed, Quality and Commercial Readiness
  • Implementing platform-based approaches to accelerate ADC development timelines.
  • Improving cell line development, process development, and analytical characterization strategies.
  • Balancing innovation, cost-efficiency, and regulatory compliance throughout product development.
10:30
Morning Break – Exhibition Viewing & 1-1 Networking
11:15
Innovative Linker Strategies: Improving Stability and Tumor-Specific Activation
  • pH-sensitive and enzymatically cleavable linkers for targeted release
  • Strategies to minimize systemic toxicity and maximize drug release efficiency
  • Engineering linkers to overcome multi-drug resistance in tumors
11:40
Overcoming ADC Resistance: Strategies for Enhancing Tumor Cell Killing
  • Mechanisms of resistance: ADC efflux, antigen loss, and lysosomal degradation
  • Combination therapies: ADCs with checkpoint inhibitors and targeted therapies
  • Approaches to optimize ADC recycling and increase intracellular payload delivery
Reserved for Solution Provider
12:05
Targeted Immune-Stimulatory Payloads: Harnessing the Immune System for ADC Therapy
  • Using ADCs to deliver immune-activating molecules directly to tumors
  • Payloads designed to stimulate T cells, NK cells, or macrophages in the tumor microenvironment
  • Combination strategies with immune checkpoint inhibitors to enhance anti-tumor responses
12:30
Lunch – Exhibition Viewing & 1-1 Networking
2:15
Advancing Clinical Progress of Next-Generation ADC Pipelines in East Asia
  • Sharing latest clinical trial updates and milestones from ongoing ADC programmes in East Asia
  • Highlighting early efficacy, safety, and translational data across solid tumour and haematology indications
  • Discussing regulatory pathways and strategies to accelerate ADC approvals in Asia and global markets
2:40
The Next Wave of ADC Approvals: Key Learnings from Recent FDA and EMA Submissions
  • Clinical trial design strategies that accelerate ADC approval
  • Overcoming safety concerns: Managing off- target toxicity
  • Case studies of recent successful ADC approvals and regulatory hurdles
Reserved for Solution Provider
3:20
Translating ADC Innovation into Clinical Success Across East Asia
  • Showcasing breakthrough clinical achievements and first-in-human data from East Asian biopharma companies
  • Sharing lessons learned from ADC clinical development, manufacturing readiness, and global partnering efforts
  • Evaluating the future landscape of ADC therapeutics including dual payloads, novel targets, and next-generation conjugation platforms
3:45
Afternoon Break – Exhibition Viewing & 1-1 Networking
4:15
Purification and Analytical Strategies for High-Quality ADCs
  • Advanced purification approaches to remove aggregates and free payloads
  • Analytical methods for characterization: DAR, stability, and impurity profiling
  • Addressing scalability challenges in downstream processing
4:40
Linker Innovation: Enhancing Stability and Controlled Drug Release
  • Cleavable vs non-cleavable linkers: design considerations and trade-offs
  • Tumor-selective release mechanisms and microenvironment triggers
  • Improving plasma stability to reduce systemic toxicity
4:55
Optimizing Payload-Linker Integration for Superior ADC Performance
  • Synergizing linker and payload design to maximize therapeutic index
  • Impact of conjugation chemistry on payload delivery and efficacy
  • Translational insights from preclinical optimization to clinical outcomes
5:20
Chairman Closing Remarks
5:25
End of Conference Day 1
6:00
ABEA Awards 2027
ADC ASIA CONGRESS 2027

Day 2

Wednesday, 24 March 2027

8:55
Chairman Opening Remarks
9:00
Enhancing ADC Yield and Consistency: Advances in Bioconjugation Technologies
  • Site-specific vs. random conjugation: Impact on ADC stability and efficacy
  • Al-driven process optimization for consistent drug-to-antibody ratio (DAR)
  • Novel bioconjugation chemistries to improve homogeneity
9:25
Engineering Beyond the First Wave of Next-Gen ADCs
  • Emerging conjugation and linker chemistries pushing past current DAR and stability limitations
  • Novel payload classes beyond topoisomerase inhibitors and their differentiated mechanisms of action
  • Adjacent modalities: bispecific ADCs, degrader-conjugates, and immune-stimulating payloads reshaping the pipeline
10:15
Purification and Formulation Strategies for ADC Manufacturing
  • Addressing aggregation and stability challenges during ADC purification
  • Advances in chromatography techniques for high-purity ADC isolation
  • Lyophilization and storage considerations for long-term ADC stability
10:30
Morning Break – Exhibition Viewing & 1-1 Networking
11:15
Enhancing ADC Performance: Tackling Toxicity and Resistance
  • Addressing dose-limiting toxicities in clinical settings
  • Overcoming resistance through novel design approaches
  • Role of dual payloads and combination strategies
11:40
Enhancing ADC Yield and Consistency: Advances in Bioconjugation Technologies
  • Site-specific vs. random conjugation: Impact on ADC stability and efficacy
  • Al-driven process optimization for consistent drug-to-antibody ratio (DAR)
  • Novel bioconjugation chemistries to improve homogeneity
Reserved for Solution Provider
12:05
Enhancing ADC Performance: Tackling Toxicity and Resistance
  • Addressing dose-limiting toxicities in clinical settings
  • Overcoming resistance through novel design approaches
  • Role of dual payloads and combination strategies
12:30
Lunch – Exhibition Viewing & 1-1 Networking
2:10
Clinical Development Updates and Future Directions for Emerging ADC Therapies
  • Presenting Phase I–III clinical progress and pipeline expansion strategies for novel ADC candidates
  • Exploring patient selection, biomarker strategies, and combination therapy approaches in clinical studies
  • Addressing key challenges in dose optimisation, toxicity management, and clinical differentiation
2:35
Dual-Targeting and Bispecific ADCs: Enhancing Tumor Selectivity
  • Development of bispecific ADCs to improve tumor penetration
  • Addressing tumor heterogeneity with dual- antigen recognition
  • Engineering strategies to reduce off-target effects
Reserved for Solution Provider
2:50
Leadership Panel Discussion: Current Market Trends and Future Directions for ADCs
  • Expanding ADC applications beyond oncology: Autoimmune diseases and infectious diseases
  • Investment trends in ADC biotech startups and big pharma partnerships
  • Navigating global regulatory requirements: Differences in approval pathways
3:15
Afternoon Break – Exhibition Viewing & 1-1 Networking
Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
4:20
Biologics Manufacturing Asia
  • Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
  • Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
  • CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?
ADC Asia Congress
  • Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
  • From Bench to Bedside: What’s Missing in Translating Preclinical ADC Wins to Clinical Success?
  • Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities
BioSupply Chain Asia
  • Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
  • Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
  • Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?
Clinical Trial Asia
  • Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
  • Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?
Oligos & Peptides Asia
  • Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
  • Beyond Purity: Managing Peptide Aggregation, Degradation & Stability
5:20
End of Conference Day 2
CELL & GENE THERAPY WORLD ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC Opening Remarks
8:55
Chairman Welcome Remarks
Next-Generation Cell & Gene Therapies: CAR-T, Gene Editing & Emerging Modalities
9:00
Panel Discussion: Next-Generation Cell & Gene Therapies: Advancing CAR-T, Gene Editing and Emerging Therapeutic Modalities in Asia
  • How are emerging technologies such as CAR-T, gene editing, and engineered immune cell therapies shaping the next generation of CGT development in Asia?
  • What are the key scientific, manufacturing, and clinical challenges that need to be addressed to accelerate CGT translation from research to patient access?
  • How can Asia strengthen its CGT ecosystem through collaboration across biotech companies, research institutions, hospitals, and manufacturing partners?
9:45
Enabling Scalable Cell & Gene Therapy Development Through Advanced Manufacturing Solutions
  • Optimising workflows for scalable CGT production
  • Improving process control, automation, and manufacturing efficiency
  • Supporting GMP readiness from development to commercialisation
Reserved for Solution Provider
10:00
Real-World Challenges in Advancing Cell & Gene Therapies: From Clinical Development to Commercial Success
  • Lessons learned from developing and translating CGT platforms
  • Overcoming manufacturing, regulatory, and operational barriers
  • Preparing next-generation therapies for broader patient access
10:25
Morning Break, Exhibition Viewing & 1-1 Networking
From Discovery to Clinical Translation: Accelerating CGT Development
11:10
Translating Innovative Cell Therapy Platforms from Discovery to Clinical Development
  • Advancing novel CGT candidates from preclinical research into human trials
  • Addressing scientific and operational barriers during development
  • Lessons learned from early-stage clinical translation
11:35
Accelerating CGT Development Through Integrated Technologies and Innovative Workflow Solutions
  • Enabling faster transition from discovery to clinical-stage development
  • Improving efficiency through advanced analytics and automation
  • Supporting reproducible and scalable CGT workflows
Reserved for Solution Provider
11:50
Building Clinical-Ready Cell & Gene Therapies: Bridging Research, Manufacturing and Patient Delivery
  • Aligning research, CMC, and clinical strategies for successful development
  • Managing technology transfer and manufacturing readiness
  • Preparing CGT programs for regulatory milestones
12:15
Accelerating CGT Innovation in Asia: Creating Pathways from Discovery to Patient Access
  • Expanding CGT development across Asia Pacific markets
  • Building collaborations between biotech, hospitals, and research institutions
  • Overcoming regulatory and commercialisation challenges
12:40
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Gene & Cell Therapy Platforms: Vector Engineering, Delivery & Analytics
2:00
Optimising Viral Vector Platforms for Next-Generation Gene Therapies
  • Advances in viral vector design and manufacturing strategies
  • Improving potency, safety, and scalability
  • Overcoming challenges in clinical translation
2:25
Enabling Next-Generation CGT Development Through Advanced Vector, Delivery and Analytical Technologies
  • Improving vector design, optimisation, and production efficiency
  • Supporting accurate characterisation and quality assessment of CGT products
  • Accelerating development timelines through innovative technology platforms
Reserved for Solution Provider
2:40
Beyond Delivery Challenges: Building Effective and Scalable Gene Therapy Platforms
  • Emerging delivery technologies for gene and cell therapies
  • Enhancing therapeutic targeting and patient outcomes
  • Lessons from clinical development programs
3:05
Harnessing Advanced Analytics to Improve CGT Development and Manufacturing Quality
  • Role of analytics in product characterisation and release testing
  • Using data-driven approaches to improve process control
  • Supporting regulatory readiness for CGT products
3:30
Afternoon Break, Exhibition Viewing & 1-1 Networking
Smart Manufacturing & Process Development for CGTs
4:10
Scaling Cell & Gene Therapy Manufacturing: From Development Processes to Commercial Production
  • Challenges in scaling CGT manufacturing operations
  • Optimising processes for consistency and quality
  • Preparing manufacturing platforms for commercial demand
4:35
Transforming CGT Manufacturing Through Automation, Digitalisation and Process Innovation
  • Enabling smarter and more efficient CGT manufacturing workflows
  • Improving process monitoring, automation, and data integration
  • Supporting GMP readiness and scalable production
Reserved for Solution Provider
4:50
Building the Future of CGT Manufacturing: Digitalisation, Automation and Operational Excellence
  • Implementing smart manufacturing strategies for advanced therapies
  • Leveraging digital tools for process optimisation
  • Improving manufacturing agility and efficiency
5:15
End of Conference Day 1
6:00
Asia Pacific Cell & Gene Therapy Excellence Awards 2027
CELL & GENE THERAPY WORLD ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC Opening Remarks
8:55
Chairman Welcome Remarks
Advanced Cell Therapies: Beyond Traditional CAR-T
9:00
Beyond CAR-T: Advancing Next-Generation Immune Cell Therapies for Improved Patient Outcomes
  • Evolution of CAR-NK, TCR-T, and engineered immune cell platforms
  • Addressing limitations of current CAR-T approaches
  • Translating novel cell therapies into clinical applications
9:25
Enabling Next-Generation Cell Therapies Through Advanced Manufacturing and Cell Engineering Technologies
  • Supporting development of innovative cell therapy platforms beyond CAR-T
  • Improving cell engineering, automation, and manufacturing workflows
  • Enabling scalable and reproducible production for clinical applications
Reserved for Solution Provider
9:40
The Future of Cell Therapy: Harnessing iPSC, Gene Editing and Universal Cell Platforms
  • Development of off-the-shelf cell therapy approaches
  • Improving scalability and manufacturing efficiency
  • Expanding access to advanced therapies
10:05
Engineering Smarter Cell Therapies: Innovation Pathways from Research to Clinical Development
  • Advances in cell engineering technologies
  • Improving therapeutic potency and safety profiles
  • Overcoming challenges in clinical translation
10:30
Morning Break, Exhibition Viewing & 1-1 Networking
Manufacturing Excellence: Scale-Up, Tech Transfer & CMC Readiness
11:10
From Clinical Manufacturing to Commercial Scale: Building Robust CGT Production Platforms
  • Challenges in scaling cell and gene therapy manufacturing
  • Developing reliable GMP manufacturing processes
  • Preparing facilities and operations for commercial supply
11:35
Enabling Scalable CGT Manufacturing Through Advanced Process Technologies and CMC Solutions
  • Supporting efficient scale-up from development to GMP production
  • Improving process control, automation, and manufacturing consistency
  • Accelerating CMC readiness for regulatory approval
Reserved for Solution Provider
11:50
Successful Tech Transfer in CGT: Bridging Development, Manufacturing and Regulatory Requirements
  • Managing technology transfer between sites and partners
  • Maintaining product quality during process changes
  • Aligning manufacturing strategies with regulatory expectations
12:15
CMC Readiness for Next-Generation Therapies: Overcoming Manufacturing and Regulatory Challenges
  • Building CMC strategies early in CGT development
  • Addressing analytical, quality, and process challenges
  • Supporting faster progression toward market approval
12:40
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Supply Chain & Operational Excellence for CGTs
2:00
From Vein-to-Vein: Optimising Cell Therapy Supply Chains for Clinical and Commercial Success
  • Managing patient-specific therapy logistics
  • Improving coordination between collection, manufacturing, and delivery
  • Reducing operational risks across the CGT journey
2:25
Building Resilient CGT Supply Chains Through Advanced Logistics, Traceability and Digital Solutions
  • Improving end-to-end visibility across CGT supply networks
  • Ensuring product integrity through temperature-controlled logistics
  • Supporting scalable operations for personalised therapies
Reserved for Solution Provider
2:40
Scaling CGT Operations: Building Infrastructure for Global Cell Therapy Delivery
  • Developing scalable operational models for growing CGT demand
  • Managing manufacturing capacity and supply continuity
  • Preparing for commercial deployment across regions
3:05
Digital Transformation in CGT Supply Chains: Enhancing Visibility, Compliance and Efficiency
  • Using digital platforms for tracking and traceability
  • Improving data integration across CGT workflows
  • Supporting regulatory compliance and operational excellence
3:30
Afternoon Break, Exhibition Viewing & 1-1 Networking
Regulatory Pathways, Market Access & Commercialization
4:10
From Approval to Adoption: Building Successful Commercial Strategies for Cell & Gene Therapies
  • Navigating regulatory pathways for advanced therapies
  • Developing market access strategies for innovative treatments
  • Preparing CGTs for commercial launch and patient availability
4:35
Commercialising Cell & Gene Therapies: Overcoming Regulatory and Healthcare System Challenges
  • Managing regulatory requirements across global markets
  • Addressing reimbursement and healthcare adoption barriers
  • Creating sustainable commercial models for CGT delivery
5:00
The Future of CGT in Asia: Building Regulatory Alignment and Expanding Patient Access
  • Regulatory evolution across Asia Pacific markets
  • Opportunities for regional CGT collaboration
  • Accelerating access to advanced therapies for patients
5:25
Chairman Closing Remarks
5:30
End of Conference
CLINICAL TRIALS FESTIVAL ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC Representative
8:55
Chairperson Opening Remarks:
APAC Trial Harmonization & Emerging Markets: Multi-country Trial Design and Next-wave Market Spotlight
9:00
One Region, Many Rules: Designing Multi-Country Trials Across APAC's Regulatory Patchwork
  • How regulatory convergence initiatives (and their limits) are shaping multi-country trial strategy today
  • Practical strategies for harmonizing trial protocols, data standards, and ethics submissions across multiple countries
  • Spotlight on next-wave markets and what sponsors need to know before expanding trials into them
  • Lessons learned from early movers on de-risking multi-country trial design in emerging markets
9:50
One Region, Infinite Complexity: Reimagining Clinical Development Across APAC
  • A big-picture reflection on the opportunities and risks of scaling clinical trials across APAC's diverse markets
  • What true regulatory and operational harmonization would mean for sponsors, sites, and patients alike
  • A call to action on how the industry can collectively unlock next-wave markets faster and more responsibly
Reserved for Technology/Solution Provider
10:15
The Future of Clinical Trials in APAC: Harmonization, Access, and the Next Wave of Markets
  • A region-wide perspective on where APAC clinical trial harmonization stands today, and where it needs to go
  • Why multi-country trial design is becoming a strategic imperative, not just an operational challenge
  • A forward-looking view on which emerging markets will define the next decade of trial activity in APAC
Naveen Jain
Naveen Jain
VP, Pre-Clinical, Panacea Biotec
10:40
MORNING TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Navigating the Future of Patient-Centric Trials: Recruitment, Retention, and Patient Diversity
11:15
Cracking the Code on Patient Recruitment: Strategies to Beat Enrollment Bottlenecks in APAC
  • How to identify and overcome region-specific barriers to patient enrollment across diverse APAC healthcare systems
  • Site selection and feasibility strategies that speed up recruitment timelines without compromising data quality
  • Using digital outreach and community partnerships to widen the recruitment funnel in underserved markets
11:40
Beyond Enrollment: Building Retention and Diversity into Trial Design
  • Designing protocols that reduce patient burden and minimize dropout across long-duration, complex studies
  • Practical approaches to embedding ethnic, geographic, and socioeconomic diversity into trial populations from the outset
  • Case studies on retention strategies that worked (and didn't) in multi-country APAC trials
Reserved for Technology/Solution Provider
12:05
The Patient-Centric Trial: Decentralized Models, Digital Tools, and Inclusive Access
  • How decentralized trial elements (telehealth, remote monitoring, e-consent) are reshaping patient experience in APAC
  • Balancing technology adoption with accessibility for patients across varying digital literacy and infrastructure levels
  • Measuring the real impact of patient-centric design on recruitment speed, retention, and data diversity
Reserved for Technology/Solution Provider
12:20
Rethinking Trial Access: Recruitment and Retention Models for a More Inclusive APAC
  • Addressing structural and cultural barriers that limit patient access to clinical trials across APAC's varied healthcare landscapes
  • Site and investigator engagement strategies that build trust and sustain patient participation through trial completion
  • Frameworks for setting and measuring diversity targets that reflect real APAC disease burden and population demographics
12:35
LUNCH, EXHIBITION VIEWING, 1-1 NETWORKING
Advancing Pre-Clinical Research Bringing the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
2:15
Advancing Clinical Progress of Next-Generation ADC Pipelines in East Asia
  • Sharing latest clinical trial updates and milestones from ongoing ADC programmes in East Asia
  • Highlighting early efficacy, safety, and translational data across solid tumour and haematology indications
  • Discussing regulatory pathways and strategies to accelerate ADC approvals in Asia and global markets
2:40
The Next Wave of ADC Approvals: Key Learnings from Recent FDA and EMA Submissions
  • Clinical trial design strategies that accelerate ADC approval
  • Overcoming safety concerns: Managing off- target toxicity
  • Case studies of recent successful ADC approvals and regulatory hurdles
Reserved for Solution Provider
3:05
Translating ADC Innovation into Clinical Success Across East Asia
  • Showcasing breakthrough clinical achievements and first-in-human data from East Asian biopharma companies
  • Sharing lessons learned from ADC clinical development, manufacturing readiness, and global partnering efforts
  • Evaluating the future landscape of ADC therapeutics including dual payloads, novel targets, and next-generation conjugation platforms
3:45
AFTERNOON TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Decentralized Trials, Digital Endpoints, and Wearables
4:15
Decentralized Trials in Practice: Scaling Digital Endpoints and Wearables Across APAC
  • Practical frameworks for implementing DCT models across APAC's varied regulatory and infrastructure landscapes
  • Validating digital endpoints and wearable-derived data for regulatory acceptance and clinical decision-making
  • Case studies on hybrid and fully decentralized trials that improved data quality and patient convenience
4:40
From Pilot to Standard: The Maturing Role of Wearables and Digital Endpoints in Clinical Trials
  • How wearables and sensor-based endpoints are moving from exploratory tools to primary and secondary trial measures
  • Overcoming data integration, standardization, and interoperability challenges across devices and platforms
  • Regulatory perspectives on qualifying digital endpoints for use in pivotal APAC and global trials
5:05
Building Trust in Decentralized Data: Technology, Compliance, and Patient Experience
  • Ensuring data integrity, privacy, and compliance when deploying remote monitoring and digital tools across APAC markets
  • Balancing sponsor technology ambitions with site and patient readiness for decentralized trial components
  • What sponsors need to know about local regulatory guidance on DCT and digital endpoint adoption in APAC
5:30
END OF CONFERENCE DAY 1
6:00
CLINICAL TRIALS EXCELLENCE AWARDS 2027
CLINICAL TRIALS FESTIVAL ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC Representative
8:55
Chairperson Opening Remarks:
AI & Digital Transformation in Trial Execution: AI in Feasibility, eSource, Protocol Design
9:00
The AI-Ready Trial: Rethinking Feasibility, Data Capture, and Protocol Design for Speed
  • What sponsors need to build AI capability into feasibility planning and site selection processes
  • Overcoming adoption barriers to AI-enabled eSource across APAC sites with varying digital maturity
  • How AI and predictive analytics are being used to design smarter, more efficient trial protocols from the outset
9:25
Smarter Trials by Design: AI's Expanding Role in Feasibility and Protocol Optimization
  • How AI is helping sponsors move from reactive to predictive feasibility planning
  • Reducing protocol amendments by using AI to stress-test trial design before activation
  • What "AI-ready" eSource infrastructure looks like, and the gaps still holding APAC sites back
Reserved for Solution Provider
9:55
Agentic and AI Transformation of Preclinical Data Analysis (tbc)
  • Why real-time eSource data capture is becoming a competitive necessity, not a nice-to-have
  • How AI is being layered onto existing data systems to flag risks and inefficiencies earlier
  • Balancing innovation speed with data integrity and regulatory expectations across APAC markets
Matthew Choo, Ph.D.
Matthew Choo, Ph.D.
Associate Director, Data Science, MSD
10:20
MORNING TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Transforming Clinical Trial Logistics in APAC [Presentations at BSCA Room]
11:10
Engineering the Next Generation of Biopharma Manufacturing: Building Scalable, Smart & Resilient Facilities
  • Connecting planning, manufacturing and logistics through integrated digital platforms
  • Using real-time data and predictive intelligence to improve end-to-end decision-making
  • Automating workflows and reducing operational complexity across the supply chain
  • Building scalable digital capabilities that strengthen resilience, agility and performance
Maneesh Ghildyal
Maneesh Ghildyal
VP & Global Head, Projects & Engineering, Biocon Biologics
11:35
Optimising Decentralised Clinical Trials Through Connected Logistics Technologies
  • Enabling direct-to-patient and site-to-patient deliveries
  • Real-time shipment visibility through connected monitoring platforms
  • Reducing risk with predictive temperature and lane analytics
  • Supporting patient-centric clinical trials with integrated logistics solutions
Reserved for Solution Provider
12:05
Transforming Clinical Trial Supply Chains for Faster & Smarter Research
  • Demand forecasting and inventory strategies
  • Enhancing visibility and coordination across sponsors, depots, and logistics partners
  • Digital technologies to improve trial supply agility while maintaining regulatory compliance
12:30
LUNCH, EXHIBITION VIEWING, 101 NETWORKING1
APAC CRO Showcase: From Early-Phase to Late-Stage: Showcasing End-to-End Clinical Research Capabilities
2:15
The Access Equation: Connecting Clinical Evidence to Market Realities in APAC
  • Turning post-authorization and real-world data into evidence that supports pricing and reimbursement decisions
  • The expanding role of medical affairs in shaping payer conversations and health technology assessments
  • Country-specific market access hurdles across APAC and how sponsors are adapting their approach
2:40
Building Seamless Clinical Development Pathways
  • The strategic advantages of consistent data, teams, and infrastructure across the entire trial lifecycle
  • How early-phase insights can directly inform and de-risk late-stage trial design and execution
  • Showcasing real-world examples of end-to-end clinical research driving faster, more efficient program delivery
3:05
After the Approval: Making Post-Authorization Data Work Harder for Market Access
  • Using post-authorization commitments as a strategic tool for generating real-world evidence, not just a regulatory obligation
  • How medical affairs functions are being restructured to support faster, more coordinated payer engagement
  • Practical approaches to closing the gap between approval and actual patient access across APAC markets
3:20
AFTERNOON TEA BREAK, EXHIBITION VIEWING, 1-1 NETWORKING
Closing Panel Discussion: Rethinking Clinical Development as a Continuous Journey
4:15
Panel Discussion: One Partner, Every Phase: Rethinking Clinical Development as a Continuous Journey
  • Why continuity from early-phase discovery through late-stage execution is becoming a competitive differentiator in APAC
  • Breaking down the operational and data silos that typically separate early and late-phase trial work
  • How end-to-end capabilities support faster, more informed go/no-go decisions across the development timeline
5:00
END OF CONFERENCE DAY 2
OLIGOS & PEPTIDES WORLD ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
Asia’s Frontier in Oligonucleotide Therapeutics
9:00
Leadership Panel: From Manufacturing Powerhouse to Innovation Leader — Can Asia Lead the Next Generation of Oligonucleotide Therapeutics?
  • Positioning APAC as a global hub for oligonucleotide discovery, development and commercialization
  • Building stronger links between biotech innovation, pharma, academia, CDMOs and investors
  • Moving Asia beyond manufacturing toward globally originated therapeutic pipelines
  • Identifying the capabilities and partnerships required to compete globally
PANELISTS
Bin Xia Yang
Bin Xia Yang
Director, Hengrui R&D Centre
9:50
Engineering the Next Generation of ASO & siRNA Therapeutics: Potency, Precision & Durability
  • Advancing ASO and siRNA design for improved potency and selectivity
  • Optimising chemical modifications to enhance stability and therapeutic performance
  • Balancing efficacy, safety, durability and dosing frequency
  • Accelerating candidate selection from discovery into clinical development
Reserved for Solution Provider
10:05
Beyond the Liver: Breaking the Extrahepatic Delivery Barrier for Oligonucleotide Therapeutics
  • Expanding delivery beyond hepatic targets into CNS, muscle, immune cells and other tissues
  • Advancing receptor- and ligand-mediated targeting approaches
  • Overcoming endosomal escape and intracellular delivery barriers
  • Translating promising delivery technologies from preclinical models into patients
10:30
Morning Tea, Exhibition Viewing & 1-1 Networking
Peptide Therapeutics 2.0 — Beyond GLP-1
11:15
Beyond GLP-1: Where Will the Next Generation of Peptide Blockbusters Come From?
  • Expanding peptide therapeutics into oncology, immunology, CNS and rare diseases
  • Identifying opportunities beyond metabolic and obesity indications
  • Advancing multi-agonist, multispecific and multifunctional peptide platforms
  • Differentiating peptides from antibodies and small molecules
11:40
Cyclic & Constrained Peptides: Unlocking Intracellular and Previously Undruggable Targets
  • Using cyclic and constrained architectures to improve affinity and selectivity
  • Accessing intracellular targets traditionally considered undruggable
  • Improving proteolytic stability, permeability and pharmacokinetics
  • Translating complex peptide scaffolds into developable drug candidates
Reserved for Solution Provider
11:55
Engineering Long-Acting Peptides: Extending Half-Life Without Compromising Potency & Safety
  • Designing peptides for extended systemic exposure and reduced dosing frequency
  • Evaluating lipidation, conjugation, depot and sustained-release strategies
  • Balancing half-life extension with potency, stability and safety
  • Developing more convenient and patient-friendly dosing strategies
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Breaking the Delivery Barrier — From Oral Peptides to Precision Oligos
2:05
Panel Discussion: Oral Peptide Delivery: Can We Finally Break the Bioavailability Barrier
  • Overcoming enzymatic degradation and gastrointestinal barriers
  • Evaluating permeation enhancers and novel formulation technologies
  • Improving oral bioavailability while maintaining safety
  • Translating promising oral peptide technologies into commercially viable therapies
2:35
Precision Peptide Delivery: Engineering Tissue-Specific & Intracellular
  • Engineering peptides to overcome membrane and physiological barriers
  • Advancing receptor-mediated and ligand-directed tissue targeting
  • Optimising biodistribution while reducing off-target exposure
  • Translating preclinical delivery performance into clinically meaningful exposure
Reserved for Solution Provider
2:50
Next-Generation Delivery Platforms for RNA & Oligonucleotide Therapeutics
  • Comparing emerging delivery technologies beyond conventional approaches
  • Exploring extracellular vesicles and other next-generation carriers
  • Improving cargo loading, cellular uptake and tissue specificity
  • Addressing scalability, manufacturability and clinical translation
Stephen Lin
Stephen Lin
Vice General Manager, ExoOne Bio
3:25
Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Networking
Convergence — Peptide–Oligonucleotide Conjugates & Hybrid Modalities
4:10
Beyond GalNAc: Peptide–Oligonucleotide Conjugates for the Next Frontier of Targeted
  • Identifying where peptide-enabled targeting can outperform existing delivery technologies
  • Expanding oligonucleotide delivery into difficult tissues and cell types
  • Comparing cell-penetrating, receptor-targeting and tissue-specific peptides
  • Determining which conjugate platforms offer the strongest clinical and commercial potential
4:35
Conjugate by Design: Engineering Peptide–Linker–Oligonucleotide Architectures for Maximum Therapeutic Performance
  • Optimising peptide, linker and oligonucleotide architecture
  • Balancing potency, selectivity, stability, PK/PD and intracellular release
  • Selecting conjugation strategies based on target tissue and mechanism
  • Using computational and AI-enabled approaches to accelerate candidate optimisation
Reserved for Solution Provider
4:55
From Chemistry to Clinic: Scaling Peptide–Oligonucleotide Conjugates for Commercial Manufacturing
  • Scaling synthesis and conjugation while maintaining yield and purity
  • Controlling conjugation-related heterogeneity and critical quality attributes
  • Overcoming purification challenges for increasingly complex molecules
  • Building scalable CMC strategies from clinical development to commercial supply
5:20
Chairman’s Closing Remarks
5:30
End of Day 1 Conference
6:00
Cocktails & Networking
6:30
Asia-Pacific Biopharma Excellence Awards 2027 Gala Dinner
OLIGOS & PEPTIDES WORLD ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
From Asia to Global Clinical Development & Regulatory Approval
9:00
Oligos:
From Asia to Global Approval: Navigating Regulatory & CMC Pathways for Oligonucleotide Therapeutics
  • Addressing oligonucleotide-specific regulatory and CMC expectations
  • Managing sequence-related impurities, chemical modifications and comparability
  • Aligning development strategies across the US, Europe, China, Japan, Korea and Singapore
  • Designing APAC programmes capable of supporting global regulatory submissions
9:25
From First-in-Human to Global Development: De-Risking Clinical Translation from Asia
  • Translating preclinical PK/PD, biodistribution and toxicology into clinical dose selection
  • Designing efficient first-in-human and early-phase trials
  • Selecting biomarkers and endpoints to demonstrate proof of mechanism
  • Using APAC clinical development to accelerate progression into global programmes
Reserved for Solution Provider
9:40
Peptides:
From Asia to Global Approval: Regulatory & CMC Strategies for Next-Generation Peptide Therapeutics
  • Addressing regulatory requirements for conventional, cyclic, modified and complex peptides
  • Establishing specifications around purity, degradation, stability and product quality
  • Managing manufacturing changes and comparability throughout development
  • Building regulatory strategies that enable Asia-developed therapies to enter global markets
10:05
From Accelerated Approval to Global Launch: Late-Stage Development & Lifecycle Strategy for Oligos and Peptides
  • Translating clinical evidence into patient access
  • Building evidence strategies for innovative therapeutics
  • Navigating regulatory and healthcare stakeholder requirements
  • Moving therapies from development toward real-world adoption
Alap Gandhi
Alap Gandhi
Country Medical Director, GSK
10:30
Morning Break, Exhibition Viewing & 1-1 Networking
Oligonucleotide Manufacturing — From Synthesis to Commercial Scale
11:15
From Clinical Supply to Commercial Manufacturing: Building Scalable Oligonucleotide Processes
  • Moving from development-scale synthesis into robust GMP manufacturing
  • Establishing scalable processes for increasing commercial deman
  • Managing technology transfer between internal facilities and CDMOs
  • Building supply strategies that support clinical and commercial growth
11:40
Scaling Oligonucleotide Synthesis: Yield, Purity, Solvent Reduction & Commercial Throughput
  • Improving coupling efficiency, cycle times and overall synthesis yield
  • Reducing solvent and reagent consumption at commercial scale
  • Managing sequence length and complexity as pipelines evolve
  • Increasing throughput without compromising product quality
Reserved for Solution Provider
11:55
Greener & Smarter Oligo Manufacturing: Can New Technologies Transform the Economics of Synthesis?
  • Reducing solvent intensity, waste and environmental footprint
  • Evaluating alternative and hybrid synthesis technologies
  • Applying automation, digitalisation and process monitoring
  • Balancing sustainability improvements with COGS and manufacturing performance
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Peptide Manufacturing — Scale, Cost & GMP Readiness
2:05
Scaling Peptide Therapeutics for Commercial Manufacturing: From Solid-Phase Synthesis to GMP & Regulatory Readiness
  • Developing robust peptide processes from bench scale to cGMP manufacturing
  • Managing process optimisation, scale-up and manufacturing transfer
  • Integrating analytical method development with peptide process development
  • Preparing peptide products for regulatory and DMF requirements across the US and Europe
Dr. Bharti Prafulla Deshmukh
Dr. Bharti Prafulla Deshmukh
HOD of RND Peptide Genric, Hovid Bhd
2:30
Reducing the Cost of Peptide Manufacturing at Commercial Scale: SPPS, LPPS & Process Intensification
  • Reducing resin, solvent and reagent consumption
  • Comparing SPPS, LPPS and hybrid manufacturing approaches
  • Improving coupling efficiency, yield and throughput
  • Identifying opportunities to significantly reduce commercial COGS
Reserved for Solution Provider
2:45
Purification: The Hidden Bottleneck in Commercial Peptide Manufacturing
  • Tackling purification challenges as peptide complexity increases
  • Improving recovery and purity without sacrificing manufacturing yield
  • Optimising chromatography and alternative purification strategies
  • Reducing purification time, solvent consumption and cost at commercial scale
3:10
From Bench to GMP: Scaling Complex Peptide Therapeutics Without Losing Quality
  • Translating laboratory processes into robust GMP manufacturing
  • Establishing CQAs and process controls during scale-up
  • Managing technology transfer and manufacturing comparability
  • Integrating analytical development with peptide process development
3:35
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Closing Roundtable Discussion: Bridging the Gaps: Practical Solutions for Manufacturing, Trials, Logistics & Drug Development in Asia
4:20
Biologics Manufacturing Asia
  • Scaling Smarter: How Can We Drive Process Intensification Without Compromising Quality?
  • Future-Proofing Biomanufacturing: What Does a Truly Agile, Digital-First Facility Look Like in Asia?
  • CMC Excellence in a Complex World: What Frameworks Enable Seamless Quality, Analytics, and Compliance?
ADC Asia Congress
  • Cracking the Code on ADC Stability: What Formulation Innovations Are Showing Real Results?
  • From Bench to Bedside: What’s Missing in Translating Preclinical ADC Wins to Clinical Success?
  • Strategic Licensing in the Asian ADC Market: Unlocking Growth Opportunities
BioSupply Chain Asia
  • Building a Smart, Resilient Cold Chain: What Technologies Are Actually Reducing Risk Today?
  • Greener Logistics: How Can APAC Balance Efficiency and Sustainability in Biopharma Supply Chains?
  • Intelligent Supply Chains: How Are AI, Blockchain, and Automation Rewiring Biopharma Operations?
Clinical Trial Asia
  • Winning Over Patients: What Engagement Strategies Are Reshaping Clinical Trial Participation in Asia?
  • Trial Tech & Trust: How Can We Ensure Data Integrity While Embracing AI in Clinical Research?
Oligos & Peptides Asia
  • Beyond Purity: Tackling Oligonucleotide Impurities & Analytical Challenges
  • Beyond Purity: Managing Peptide Aggregation, Degradation & Stability
5:20
Chairman’s Closing Remarks
5:30
End of Day 2 Conference
BIOSUPPLY CHAIN ASIA 2027

Day 1

Tuesday, 23 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
9:00
Leadership Panel: Building Resilient & Future-Ready Biopharma Supply Chains in Asia
  • Supply network redesign under geopolitical uncertainty
  • Key capabilities for the next five years
  • Collaboration models with logistics partners for regional agility
9:45
Designing Digital Supply Chain Control Towers for End-to-End Visibility
  • End-to-end shipment visibility
  • Predictive risk monitoring across lanes
  • Integrated logistics partner platforms
  • Real-time analytics for disruption reduction
Reserved for Solution Provider
10:00
Building Agile Biopharma Supply Networks Across Asia
  • Regional manufacturing diversification
  • Supplier resilience strategies
  • Biologics inventory optimization
  • Disruption response frameworks
Chris Chan
Chris Chan
Head of Supply Chain, APAC, Ipsen
10:25
Morning Tea, Exhibition Viewing & 1-1 Networking
11:10
Managing Temperature-Sensitive Biologics Across Global Networks
  • Cold chain risk management
  • Lane qualification
  • Product integrity assurance
  • Last-mile delivery performance
11:35
Advancing Smart Cold Chain Monitoring with IoT and Sensors
  • Real-time temperature monitoring
  • IoT shipment visibility
  • Exception management systems
  • Remote monitoring technologies
Reserved for Solution Provider
11:50
Robotics and Automated Storage and Retrieval Systems (ASRS) in Controlled Environments
  • AGVs in qualified -20°C environments for safety and accuracy
  • High-density urban clinical distribution storage optimisation
  • WMS integration with global logistics control towers
  • Reduced picking errors for patient-specific therapies
12:15
Advancing Cold Chain Excellence for Next-Generation Biopharmaceuticals
  • End-to-end temperature-controlled logistics across Asia
  • Real-time monitoring and predictive analytics to improve cold chain performance
  • Balancing compliance, product integrity, and cost efficiency for high-value biologics
12:40
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
2:00
Decarbonising Global Biopharma Logistics Without Compromising Product Quality
  • Sustainable transport strategies
  • Scope 3 emissions reduction
  • Greener distribution networks
  • Sustainability measurement frameworks
2:25
Balancing ESG Goals with Supply Chain Performance
  • Supplier sustainability programmes
  • Sustainable procurement decisions
  • Carbon reporting expectations
  • Circular supply chain initiatives
Reserved for Service Provider
2:40
Designing Reusable Packaging Loops Across Highly Fragmented Asian Lanes
  • Return logistics for temperature-controlled containers
  • Maintenance and validation of reusable shippers
  • ROI modelling for reusable vs disposable packaging
  • Customs recognition for reusable assets
3:05
Afternoon Tea, Exhibition Viewing & 1-1 Networking
3:50
Intelligent Packaging Solutions for Next-Generation Biologics
  • Smart reusable packaging for biologics and vaccines
  • Embedded IoT sensors for real-time monitoring
  • Predictive analytics for shipment performance
  • Reduced product loss and sustainability gains
4:15
Strengthening Global Traceability Across Temperature-Sensitive Supply Chains
  • End-to-end serialization strategies
  • Manufacturing-to-patient traceability
  • Anti-counterfeit data systems
  • Regulatory alignment for global compliance
Reserved for Service Provider
4:30
Digital Platforms for End-to-End Supply Chain Orchestration
  • Connected planning systems
  • Digital twins
  • AI scenario modelling
  • Supply chain automation
4:55
End of Conference Day 1
6:00
Asia-Pacific Biopharma Excellence Awards 2027 Gala Dinner
BIOSUPPLY CHAIN ASIA 2027

Day 2

Wednesday, 24 March 2027

8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
9:00
Leadership Panel: Balancing ESG Goals with Supply Chain Performance
  • How can organizations balance sustainability goals with supply chain performance?
  • What role do procurement and supplier partnerships play in achieving ESG targets?
  • How can companies measure and reduce Scope 3 emissions across the supply chain?
  • What innovations are driving circularity and greener logistics in biopharma?
9:45
Driving Enterprise-Wide Digital Transformation Across Manufacturing & Logistics (TBC)
  • Connecting planning, manufacturing and logistics through integrated digital platforms
  • Using real-time data and predictive intelligence to improve end-to-end decision-making
  • Automating workflows and reducing operational complexity across the supply chain
  • Building scalable digital capabilities that strengthen resilience, agility and performance
Reserved for Solution Provider
10:00
Transforming Global Supply Chain Planning Through AI and Advanced Analytics
  • Predictive planning
  • Intelligent inventory optimisation
  • Data-driven operational excellence
  • Building resilient digital ecosystems
Santi Purwantini
Santi Purwantini
Planning Lead, Organon
10:25
Morning Tea, Exhibition Viewing & 1-1 Networking
11:10
Engineering the Next Generation of Biopharma Manufacturing: Building Scalable, Smart & Resilient Facilities
  • Connecting planning, manufacturing and logistics through integrated digital platforms
  • Using real-time data and predictive intelligence to improve end-to-end decision-making
  • Automating workflows and reducing operational complexity across the supply chain
  • Building scalable digital capabilities that strengthen resilience, agility and performance
Maneesh Ghildyal
Maneesh Ghildyal
VP & Global Head, Projects & Engineering, Biocon Biologics
11:35
Optimising Decentralised Clinical Trials Through Connected Logistics Technologies
  • Enabling direct-to-patient and site-to-patient deliveries
  • Real-time shipment visibility through connected monitoring platforms
  • Reducing risk with predictive temperature and lane analytics
  • Supporting patient-centric clinical trials with integrated logistics solutions
Reserved for Solution Provider
11:50
Transforming Clinical Trial Supply Chains for Faster & Smarter Research
  • Demand forecasting and inventory strategies
  • Enhancing visibility and coordination across sponsors, depots, and logistics partners
  • Digital technologies to improve trial supply agility while maintaining regulatory compliance
12:15
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
2:00
Maintaining Cold Chain Compliance Across Global Distribution Networks
  • GDP best practices
  • Cold chain qualification
  • Supplier oversight
  • Audit preparedness
2:25
Advancing Singapore as Asia's Trusted Biopharma Manufacturing Hub
  • Singapore's Manufacturing 2030 strategy
  • Building resilient biopharma supply chains
  • Public-private partnerships driving innovation
  • Future investments in advanced biomanufacturing
Reserved for Service Provider
2:40
Strengthening Global GxP Compliance Across Complex Biopharma Supply Chains
  • Building harmonised GxP quality systems across global operations
  • Strengthening supplier qualification, oversight, and risk management
  • Leveraging digital technologies to improve compliance, traceability, and inspection readiness
  • Driving continuous quality improvement while maintaining supply chain resilience
Emma Dernelley
Emma Dernelley
Senior Director, Distribution & Regional Quality APAC, BeOne Medicines
3:05
Afternoon Tea, Exhibition Viewing & 1-1 Networking
3:50
Leadership Panel: Future-Proofing Biopharma Supply Chains in Asia 2027-2030
  • What will define Asia's next-generation biopharma supply chain?
  • How can organizations accelerate AI and digital transformation without compromising quality and compliance?
  • What's the one priority supply chain leaders should focus on to stay competitive over the next five years?
4:35
Aligning Manufacturing, Supply Chain & Market Access
  • Coordinating manufacturing, supply planning, and commercial teams for successful product launches
  • Managing demand uncertainty during new product introductions
  • Ensuring supply continuity while accelerating speed to market
5:00
Chairman Closing Remarks
5:05
End of Conference

Awards & Recognition

Asia-Pacific Biopharma Excellence Awards 2027
23rd March 2027 | Sands Expo & Convention Centre, Singapore
The Asia-Pacific Biopharma Excellence Awards (ABEA) 2027 aims to honour exceptional achievements in the Asian biopharma sector, recognizing excellence in bioprocessing, logistics and supply chain management, antibody-drug conjugates (ADC), and clinical trials over the past year. Celebrating the remarkable contributions of leading biopharma professionals, organizations, and technologies, the awards spotlight trailblazing leaders and trendsetters shaping the industry's future while inspiring innovation for tomorrow’s biopharma landscape.
Learn More About Our Awards
By Profile
Asian Biopharma
45%
International Biopharma
20%
CMOs
15%
Academic & Research Institutes
10%
Technology & Service Providers
10%
By Job Title
VPs & Directors of Process Development
25%
USP & DSP Specialists & Researchers
25%
Head of Quality Assurance & Analytics
20%
Head of Manufacturing & Bioprocessing
15%
Business Development & Marketing
15%
By Geography
World Map
25%
Korea & Japan
18%
China, Taiwan & Hong Kong
25%
Singapore
20%
Indonesia, Australia, Thailand, India & Malaysia
12%
USA & Europe
25%
Korea & Japan
18%
China, Taiwan & Hong Kong
25%
Singapore
20%
Indonesia, Australia, Thailand, India & Malaysia
12%
USA & Europe

Who Should Sponsor?

BIOMANUFACTURING SOFTWARE
CELL CULTURE AND FERMENTATION
PROCESS OPTIMIZATION
CRYOPRESERVATION
HIGH-THROUGHPUT SCREENING
MICROFLUIDICS
BIOSENSOR TECHNOLOGY
GENE THERAPY TECHNOLOGY
SINGLE-USE TOOLS
DRUG DELIVERY
BIOPROCESSING EQUIPMENT
CELL LINE DEVELOPMENT
NEXT-GENERATION SEQUENCING
BIOINFORMATICS & COMPUTATIONAL MODELLING
AUTOMATION AND ROBOTICS
3D BIOPRINTING
GENE EDITING
CONTINUOUS MANUFACTURING
LINKER & PAYLOAD DEVELOPMENT
PROCESS DEVELOPMENT & CDMOS
FORMULATION DEVELOPMENT
BIOCONJUGATION CHEMISTRY
REGULATORY SUPPORT
PRE-CLINICAL DEVELOPMENT & CLINICAL TRIAL SUPPLY & MANAGEMENT & CROS
FILL-FINISH PACKAGING
CDMOS, CROS & ADC SERVICE PROVIDERS
ANALYTICAL TESTING & QUALITY CONTROL
CONTRACT RESEARCH ORGANIZATIONS
DIAGNOSTICS & ANALYTICAL TOOLS
LAB EQUIPMENT STERILIZATION/PURIFICATION EQUIPMENT
LOGISTICS SERVICE PROVIDERS
ENGINEERING/FACILITY/DESIGN
INTERNATIONAL CMOS
CELL-LINES, CELL CULTURE MEDIA/LAB EQUIPMENT
COLD CHAIN
ECLINICAL PLATFORMS
MEDICAL IMAGING
CLINICAL TRIALS COMPANIES
CLINICAL DATA MANAGEMENT
MEDICAL MONITORING & BIOSTATISTICS
BIOMARKERS
LAB DESIGN
SAFETY DATA REVIEW
AIRLINES & CONSULTANTS
ACTIVE PACKAGING
PASSIVE PACKAGING
WAREHOUSE & STORAGE PROVIDERS
DRUG DISTRIBUTORS
TEMPERATURE MONITORING SOLUTIONS
3PLS
LOGISTICS AUTOMATION & ROBOTICS
AI & DIGITALIZATION
COLD CHAIN EQUIPMENT
FREIGHT FORWARDERS
SHIPPING COMPANIES
PROCUREMENT SOLUTIONS
SCM MANAGEMENT
TRACKING SOLUTIONS
COMPLIANCE SOLUTION
ULTRA COLD CHAIN
SPONSORSHIP BENEFITS

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases across the six Confex programmes.

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Our Past Partners

Sartorius Logo
Becton_Dickinson_logo.svg
IDBS_Logo
WuXi Biologics
Merck
solventum-logo-horz-clr-pos-rgb
Pfanstiehl-hd
DYE logo blue 1
Aurigene
lonza
cytiva-logo-vector
avantor-inc-logo-vector
Charles_River_Laboratories_Logo.svg
Truking logo 1
cellist-1
watson-marlow (1)
Aber
Single Use Support
PharmNXT Logo_COLOUR_transparent 2K
Tosoh Bioscience
Emerson_Electric_Company
Dr Paul Lohman
Genscript GS_Logo_Primary_RGB
Acro Biosystems
Shimadzu 1
Tofflon
Jiuzhou
IKA_Logo
Gerresheimer 2
Imalife
Lisure Science
Ellab_Logo_tagline_CYAN 2_page-0001
airdynamics
unither-pharma
ATUM_RGB_Black 1
Sanisure
SHENTEK logo
Duoning-Logo-EN-small-1
Evonik
Biomed Logo (Dark Blue & Light Blue) (1) (1)
novo-nordisk
SGS_Logo.svg
Sphere Bio-use this Dark Green WSTB Primary@300x-8 1
Biohaus Media (Media Partner) Logo
BioPharma Asia Logo
Agilent-Logo-Site
Refeyn-01
SCHOTT AG
Wuxi XDC_logo_4C
LabCorp_logo
Huida Biotech
Asymbio
Asymchem_Logo
sigma-aldrich
BSP logo 1
Akesa-Logo-1
Almac Group
austrade-logo
Australian-High-Commission
Catalent-Pharma Services-TM-Logo-Color-RGB 2
Clarivate_Logo
deep-intelligent-pharma
equilab_international_logo 1
fenix-white-plate
HMRILogo_rgb_wide
ICON
Investment-NSW-WEB_2099d4f6c3
IQVIA Biotech Logo Teal 1
komtur (1)
Nucleus Network.-1
Shanhu
Southern Star Research
SRM
the DPO centre ltd
University of Newcastle
world courier logo
Cold Chain T_Logo_With_Tagline_color
peli_logo_full_color
MarkenLogo_use this_UPSHC-PL_FULL-COLOR_RGB (5) 2
Tower Cold Chain
db schenker
doubleday acquisitions
Emballiso
abu dhabi ports
Turkish_Airlines_logo
envirotainer logo
ups-asia-group
the royale international
CRYOPDP-Logo-LHS-RGB (3) (1) (1) (1)
Biocair
Fedex-logo
Intelius
phse logo
Etihad-Airways-Logo
Beijing CIMC
Time_matters_logo
bluecrux
lufthansa cargo
Qickstat
DHL_Global_Forwarding
GCCS
Willog
and many more...

Exhibition

Exhibition Floorplan

Roselle Simpor, Sands Expo & Convention Centre, Singapore. 23 - 24 March 2027.

Max height 2.5 m MAIN DESSERT / BREAK APPETISER MAIN DESSERT / BREAK LIVE STATION COFFEE COFFEE APPETISER COFFEE DESSERT / BREAK MAIN LOUNGE MAIN STAGE 63 Stand 63 · 6 sqm (3 m x 2 m) 62 Stand 62 · 6 sqm (3 m x 2 m) 61 Stand 61 · 6 sqm (3 m x 2 m) 60 Stand 60 · 6 sqm (3 m x 2 m) 59 Stand 59 · Cytiva · 6 sqm (3 m x 2 m) 58 Stand 58 · Cytiva · 6 sqm (3 m x 2 m) 57 Stand 57 · 6 sqm (3 m x 2 m) 56 Stand 56 · Endress+Hauser · 6 sqm (3 m x 2 m) 55 Stand 55 · 6 sqm (3 m x 2 m) 54 Stand 54 · 6 sqm (3 m x 2 m) 53 Stand 53 · 3CON · 6 sqm (3 m x 2 m) 52 Stand 52 · BD · 6 sqm (3 m x 2 m) 40 Stand 40 · 6 sqm (3 m x 2 m) 41 Stand 41 · 6 sqm (3 m x 2 m) 42 Stand 42 · 6 sqm (3 m x 2 m) 43 Stand 43 · 6 sqm (3 m x 2 m) 44 Stand 44 · Cytiva · 6 sqm (3 m x 2 m) 45 Stand 45 · Cytiva · 6 sqm (3 m x 2 m) 46 Stand 46 · 6 sqm (3 m x 2 m) 47 Stand 47 · Merck · 6 sqm (3 m x 2 m) 48 Stand 48 · DrM, Dr. Mueller AG · 6 sqm (3 m x 2 m) 49 Stand 49 · 6 sqm (3 m x 2 m) 50 Stand 50 · Shanghai Duoning Biotechnology · 6 sqm (3 m x 2 m) 51 Stand 51 · BD · 6 sqm (3 m x 2 m) 39 Stand 39 · 6 sqm (3 m x 2 m) 38 Stand 38 · 6 sqm (3 m x 2 m) 37 Stand 37 · 6 sqm (3 m x 2 m) 36 Stand 36 · INFORS HT · 6 sqm (3 m x 2 m) 35 Stand 35 · 6 sqm (3 m x 2 m) 34 Stand 34 · Tofflon · 6 sqm (3 m x 2 m) 33 Stand 33 · Tosoh · 6 sqm (3 m x 2 m) 32 Stand 32 · Single Use Support · 6 sqm (3 m x 2 m) 31 Stand 31 · 6 sqm (3 m x 2 m) 30 Stand 30 · Truking · 6 sqm (3 m x 2 m) 29 Stand 29 · Hunan Honya Biotech · 6 sqm (3 m x 2 m) 28 Stand 28 · WuXi Biologics · 6 sqm (3 m x 2 m) 16 Stand 16 · 6 sqm (3 m x 2 m) 17 Stand 17 · 6 sqm (3 m x 2 m) 18 Stand 18 · 6 sqm (3 m x 2 m) 19 Stand 19 · 6 sqm (3 m x 2 m) 20 Stand 20 · 6 sqm (3 m x 2 m) 21 Stand 21 · Aber Instruments · 6 sqm (3 m x 2 m) 22 Stand 22 · 6 sqm (3 m x 2 m) 23 Stand 23 · ORKA Consulting Partners · 6 sqm (3 m x 2 m) 24 Stand 24 · Nona Biosciences · 6 sqm (3 m x 2 m) 25 Stand 25 · Pfanstiehl · 6 sqm (3 m x 2 m) 26 Stand 26 · 6 sqm (3 m x 2 m) 27 Stand 27 · PharmNXT Biotech · 6 sqm (3 m x 2 m) 93 Stand 93 · 6 sqm (3 m x 2 m) 92 Stand 92 · 6 sqm (3 m x 2 m) 80 Stand 80 · 6 sqm (3 m x 2 m) 81 Stand 81 · 6 sqm (3 m x 2 m) 79 Stand 79 · 6 sqm (3 m x 2 m) 78 Stand 78 · 6 sqm (3 m x 2 m) 64 Stand 64 · 6 sqm (3 m x 2 m) 65 Stand 65 · 6 sqm (3 m x 2 m) 91 Stand 91 · 6 sqm (3 m x 2 m) 90 Stand 90 · 6 sqm (3 m x 2 m) 82 Stand 82 · 6 sqm (3 m x 2 m) 83 Stand 83 · 6 sqm (3 m x 2 m) 77 Stand 77 · 6 sqm (3 m x 2 m) 76 Stand 76 · 6 sqm (3 m x 2 m) 66 Stand 66 · 6 sqm (3 m x 2 m) 67 Stand 67 · 6 sqm (3 m x 2 m) 89 Stand 89 · 6 sqm (3 m x 2 m) 88 Stand 88 · 6 sqm (3 m x 2 m) 84 Stand 84 · 6 sqm (3 m x 2 m) 85 Stand 85 · 6 sqm (3 m x 2 m) 75 Stand 75 · 6 sqm (3 m x 2 m) 74 Stand 74 · 6 sqm (3 m x 2 m) 68 Stand 68 · 6 sqm (3 m x 2 m) 69 Stand 69 · 6 sqm (3 m x 2 m) 86 Stand 86 · 6 sqm (3 m x 2 m) 87 Stand 87 · 6 sqm (3 m x 2 m) 73 Stand 73 · 6 sqm (3 m x 2 m) 72 Stand 72 · QuickSTAT · 6 sqm (3 m x 2 m) 70 Stand 70 · 6 sqm (3 m x 2 m) 71 Stand 71 · 6 sqm (3 m x 2 m) 15 Stand 15 · UniQCulture · 1 sqm (1 m x 1 m) 14 Stand 14 · 6 sqm (3 m x 2 m) 13 Stand 13 · 6 sqm (3 m x 2 m) 12 Stand 12 · Dou Yee Enterprises · 6 sqm (3 m x 2 m) 11 Stand 11 · Sartorius · 6 sqm (3 m x 2 m) 10 Stand 10 · Sartorius · 6 sqm (3 m x 2 m) 9 Stand 9 · Avantor · 6 sqm (3 m x 2 m) 8 Stand 8 · Thermo Fisher Scientific · 6 sqm (3 m x 2 m) 7 Stand 7 · Andgel Industrial Shanghai · 6 sqm (3 m x 2 m) 6 Stand 6 · Catalent · 6 sqm (3 m x 2 m) 94 Stand 94 · 6 sqm (3 m x 2 m) 95 Stand 95 · 6 sqm (3 m x 2 m) 1 Stand 1 · 6 sqm (3 m x 2 m) 2 Stand 2 · GenScript ProBio · 6 sqm (3 m x 2 m) 3 Stand 3 · Hyqure · 4 sqm (2 m x 2 m) 5 Stand 5 · 6 sqm (3 m x 2 m) 4 Stand 4 · BSP Pharmaceuticals · 6 sqm (3 m x 2 m) ENTRANCE ENTRANCE ENTRANCE ENTRANCE ENTRANCE
Booked Reserved Available 6 sqm (3 m x 2 m) 4 sqm (2 m x 2 m) 1 sqm (1 m x 1 m) Select an exhibitor to find their stand. Floorplan is subject to change.
PARTNER WITH US

Sponsorship Packages

Tailored sponsorship opportunities designed to maximize your brand visibility and lead generation.

Platinum Sponsor

Speaking & thought leadership

  • 1 Conference presentation: 20 min (+ 5 min live Q&A). In the main conference sessions.
  • 1 End-user client case study: 20 min (+ 5 min live Q&A). Complimentary, in the main conference sessions.
  • 1 Pre-conference workshop: Half day (catered for 30 pax). Room hire and one refreshment included. Limited to 1 - 2 sponsors.
  • 1 Conference chairmanship: Day 2. Optional and subject to availability.
  • 1 Pre-event speaker interview. Shared with the Biopharma APAC Confex community and on social media.

Exhibition

  • 1 Exhibition space: 12 sqm (6 × 2 m table-top, upgrade to 18 sqm). In the Exhibition Hall. All upgrades are complimentary.

Passes & networking

  • 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
  • 7 Conference passes. Premium conference sessions and the Exhibition Hall.
  • 2 Exhibitor passes. To staff the booth.
  • 5 1:1 meeting assistance. Help setting up meetings on site with targeted companies.

Branding & reach

  • 1 Logo placement: Priority. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
  • 1 Corporate profile online: 200 words. Maximum length, on the official event web page.
  • 1 Brochure distribution. At the registration desk or conference table.
  • 1 Corporate gift distribution. Optional.
  • 1 In-depth post-event report. Exclusive to sponsors.
Gold Sponsor

Speaking & thought leadership

  • 1 Conference presentation: 20 min (+ 5 min live Q&A). In the main conference sessions.
  • 1 Panel or roundtable moderator. Complimentary.
  • 1 Pre-event speaker interview. Shared with the Biopharma APAC Confex community and on social media.

Exhibition

  • 1 Exhibition space: 9 sqm (4.5 × 2 m table-top, upgrade to 12 sqm). In the Exhibition Hall. All upgrades are complimentary.

Passes & networking

  • 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
  • 6 Conference passes. Premium conference sessions and the Exhibition Hall.
  • 2 Exhibitor passes. To staff the booth.
  • 5 1:1 meeting assistance. Help setting up meetings on site with targeted companies.

Branding & reach

  • 1 Logo placement: Priority. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
  • 1 Corporate profile online: 150 words. Maximum length, on the official event web page.
  • 1 Brochure distribution. At the registration desk or conference table.
  • 1 Corporate gift distribution. Optional.
  • 1 In-depth post-event report. Exclusive to sponsors.
Silver Sponsor (Enhanced)

Speaking & thought leadership

  • 1 Conference presentation: 25 min (with live Q&A). In the main conference sessions.

Exhibition

  • 1 Exhibition space: 6 sqm (3 × 2 m table-top, upgrade to 9 sqm booth). In the Exhibition Hall. All upgrades are complimentary.

Passes & networking

  • 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
  • 4 Conference passes. Premium conference sessions and the Exhibition Hall.
  • 2 Exhibitor passes. To staff the booth.

Branding & reach

  • 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners. Credited as Silver Sponsor.
  • 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
  • 1 In-depth post-event report. Exclusive to sponsors.
Silver Sponsor

Speaking & thought leadership

  • 1 Conference presentation: 15 min (with live Q&A). In the main conference sessions.

Exhibition

  • 1 Exhibition space: 6 sqm (3 × 2 m table-top). In the Exhibition Hall. All upgrades are complimentary.

Passes & networking

  • 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
  • 3 Conference passes. Premium conference sessions and the Exhibition Hall.
  • 2 Exhibitor passes. To staff the booth.

Branding & reach

  • 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
  • 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
  • 1 In-depth post-event report. Exclusive to sponsors.
Bronze Sponsor

Speaking & thought leadership

  • 1 Conference presentation: 15 min (with live Q&A). In the main conference sessions.

Exhibition

  • 1 Exhibition space: 1 sqm (upgrade to 6 sqm for first-time clients). In the Exhibition Hall. All upgrades are complimentary. Space for a banner display and/or a small networking table. The upgrade, to a 3 × 2 m table-top, is a one-time offer.

Passes & networking

  • 1 Speaker pass. Premium conference sessions and the Exhibition Hall.
  • 1 Conference passes. Premium conference sessions and the Exhibition Hall.

Branding & reach

  • 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
  • 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
  • 1 In-depth post-event report. Exclusive to sponsors.
Exhibitor

Exhibition

  • 1 Exhibition space: 6 sqm (3 × 2 m table-top). In the Exhibition Hall. All upgrades are complimentary.

Passes & networking

  • 2 Conference passes. Premium conference sessions and the Exhibition Hall.
  • 2 Exhibitor passes. To staff the booth.

Branding & reach

  • 1 Logo placement: Standard. Official brochure front page (sent to 20,000+ targeted senior executives), event web page with a two-way link, every event ad in media partners' publications and IMAPAC's marketing including social media, and the backdrop, on-site signage and event banners.
  • 1 Promotional video: 1 - 2 min. Played in the ad slots across both event days.
  • 1 Corporate profile online: 100 words. Maximum length, on the official event web page.
  • 1 In-depth post-event report. Exclusive to sponsors.

Be a Part of This Event!

Don't miss out on unique networking, speaking and sponsorship opportunities.

Register Here!
Head of Production
Lara Santiago
+63 9176 210686
Senior Conference Producer
Melina Dass
+65 6230 3594
Conference Producer
Umairoh Nurul Hafifa
+62 856 0026 7725 | +65 6371 9704
Conference Producer
Dee Calucin
+65 6230 3595
Portfolio Specialist
Caterin Sanggita
+65 6983 6137 | +62 811654788
Business Development Manager
Ana Laxamana
+65 6983 6132
Business Development Manager
Nathan Grace Niño
+65 6983 6134 | +44 161 552 8521
Senior Networking Delegate Executive
Niti Gupta
+65 6990 1633